Anil Matai, former managing director of Zydus Healthcare, and Vijender Singh, former chief executive officer of Metropolis Healthcare, join Jashvik Capital
Jashvik Capital, an India-focused growth private equity firm has announced the appointment of Anil Matai and Vijender Singh as operating partners.
Naresh Patwari, Founder, Jashvik Capital said, “We are excited to announce that Anil and Vijender are joining Jashvik Capital to help drive our mission. They have deep networks in healthcare/pharma and various consumption-linked sectors. Anil and Vijender have decades-long experience in building best-in-class organisations, scaling them and establishing commanding market leadership positions. We hope to partner with exceptional founders and management teams and help them realize their vision and strategies; and we are glad to have talented leaders like Anil and Vijender onboard to help undertake this journey”
Vijender Singh was most recently CEO of Metropolis Healthcare and COO of Dr. Lal’s Pathlabs. He helped scale both these companies under private equity ownership. Previously, he held leadership roles at Ranbaxy Labs, in their OTC/Wellness business, and at Bausch & Lomb. Anil Matai was most recently, managing director of Zydus Healthcare and CEO of Novartis Pharma India. Previously, he also held leadership positions at GlaxoSmithKline India.
Jashvik Capital is a SEBI (Securities and Exchange Board of India) registered Category II Alternative Investment Fund. The firm will invest alongside founders of high quality, profitable growth businesses in large addressable markets in healthcare and consumption-linked sectors.